Morgan Stanley Igm Biosciences, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 101,095 shares of IGMS stock, worth $842,121. This represents 0.0% of its overall portfolio holdings.

Number of Shares

101,095

Previous 95,041 6.37%

Holding current value

$842,121

Previous $789,000 23.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.68 - $17.36 $52,548 - $105,097	6,054 Added 6.37%	101,095 $975,000
Q4 2023 Feb 13, 2024	BUY	$3.94 - $8.79 $83,713 - $186,761	21,247 Added 28.79%	95,041 $789,000
Q3 2023 Nov 15, 2023	SELL	$6.66 - $10.64 $174,105 - $278,150	-26,142 Reduced 26.16%	73,794 $616,000
Q2 2023 Aug 14, 2023	BUY	$8.86 - $14.0 $161,712 - $255,528	18,252 Added 22.34%	99,936 $922,000
Q1 2023 May 15, 2023	SELL	$13.74 - $25.76 $138,128 - $258,965	-10,053 Reduced 10.96%	81,684 $1.12 Million

Q4 2022 Feb 14, 2023	SELL	$15.45 - $26.02 $127,555 - $214,821	-8,256 Reduced 8.26%	91,737 $1.56 Million
Q3 2022 Nov 14, 2022	SELL	$15.42 - $27.01 $387,797 - $679,274	-25,149 Reduced 20.1%	99,993 $2.27 Million
Q2 2022 Oct 27, 2022	BUY	$13.27 - $25.5 $378,885 - $728,076	28,552 Added 29.56%	125,142 $2.26 Million
Q2 2022 Aug 15, 2022	BUY	$13.27 - $25.5 $378,885 - $728,076	28,552 Added 29.56%	125,142 $2.26 Million
Q1 2022 Oct 27, 2022	SELL	$13.42 - $29.73 $383,167 - $848,850	-28,552 Reduced 22.82%	96,590 $2.58 Million
Q1 2022 May 13, 2022	BUY	$13.42 - $29.73 $612,099 - $1.36 Million	45,611 Added 89.47%	96,590 $2.58 Million
Q4 2021 Feb 14, 2022	BUY	$27.59 - $66.39 $153,427 - $369,194	5,561 Added 12.24%	50,979 $1.5 Million
Q3 2021 Nov 15, 2021	BUY	$65.76 - $90.65 $2.99 Million - $4.12 Million	45,418 New	45,418 $2.99 Million

Others Institutions Holding IGMS

# of Institutions

Shares Held

20.5M

Call Options Held

11.1K

Put Options Held

5.1K

View Full List

About IGM Biosciences, Inc.

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $241M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

More about IGMS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account